Robert J Miller1, John M Thompson1, Jesse Zheng2, Mark C Marchitto1, Nathan K Archer1, Bret L Pinsker1, Roger V Ortines1, Xuesong Jiang2, Russell A Martin2, Isabelle D Brown1, Yu Wang1, Robert S Sterling1, Hai-Quan Mao2, Lloyd S Miller1,2. 1. Departments of Dermatology (R.J.M., M.C.M., N.K.A., B.L.P., R.V.O., I.D.B., Y.W., and L.S.M.) and Orthopaedic Surgery (J.M.T., R.S.S., and L.S.M.) and Division of Infectious Diseases, Department of Medicine (L.S.M.), Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Departments of Biomedical Engineering (J.Z.) and Materials Science and Engineering (X.J., R.A.M., H.-Q.M., and L.S.M.), Translational Tissue Engineering Center (X.J., R.A.M., H.-Q.M., and L.S.M.), Institute for NanoBioTechnology (X.J., R.A.M., and H.-Q.M.), and Whitaker Biomedical Engineering Institute (H.-Q.M.), Johns Hopkins University, Baltimore, Maryland.
Abstract
BACKGROUND: In vivo bioluminescence imaging (BLI) provides noninvasive monitoring of bacterial burden in animal models of orthopaedic implant-associated infection (OIAI). However, technical limitations have limited its use to mouse and rat models of OIAI. The goal of this study was to develop a larger, rabbit model of OIAI using in vivo BLI to evaluate the efficacy of an antibiotic-releasing implant coating. METHODS: A nanofiber coating loaded with or without linezolid-rifampin was electrospun onto a surgical-grade locking peg. To model OIAI in rabbits, a medial parapatellar arthrotomy was performed to ream the femoral canal, and a bright bioluminescent methicillin-resistant Staphylococcus aureus (MRSA) strain was inoculated into the canal, followed by retrograde insertion of the coated implant flush with the articular surface. In vivo BLI signals were confirmed by ex vivo colony-forming units (CFUs) from tissue, bone, and implant specimens. RESULTS: In this rabbit model of OIAI (n = 6 rabbits per group), implants coated without antibiotics were associated with significantly increased knee width and in vivo BLI signals compared with implants coated with linezolid-rifampin (p < 0.001 and p < 0.05, respectively). On day 7, the implants without antibiotics were associated with significantly increased CFUs from tissue (mean [and standard error of the mean], 1.4 × 10 ± 2.1 × 10 CFUs; p < 0.001), bone (6.9 × 10 ± 3.1 × 10 CFUs; p < 0.05), and implant (5.1 × 10 ± 2.2 × 10 CFUs; p < 0.05) specimens compared with implants with linezolid-rifampin, which demonstrated no detectable CFUs from any source. CONCLUSIONS: By combining a bright bioluminescent MRSA strain with modified techniques, in vivo BLI in a rabbit model of OIAI demonstrated the efficacy of an antibiotic-releasing coating. CLINICAL RELEVANCE: The new capability of in vivo BLI for noninvasive monitoring of bacterial burden in larger-animal models of OIAI may have important preclinical relevance.
BACKGROUND: In vivo bioluminescence imaging (BLI) provides noninvasive monitoring of bacterial burden in animal models of orthopaedic implant-associated infection (OIAI). However, technical limitations have limited its use to mouse and rat models of OIAI. The goal of this study was to develop a larger, rabbit model of OIAI using in vivo BLI to evaluate the efficacy of an antibiotic-releasing implant coating. METHODS: A nanofiber coating loaded with or without linezolid-rifampin was electrospun onto a surgical-grade locking peg. To model OIAI in rabbits, a medial parapatellar arthrotomy was performed to ream the femoral canal, and a bright bioluminescent methicillin-resistant Staphylococcus aureus (MRSA) strain was inoculated into the canal, followed by retrograde insertion of the coated implant flush with the articular surface. In vivo BLI signals were confirmed by ex vivo colony-forming units (CFUs) from tissue, bone, and implant specimens. RESULTS: In this rabbit model of OIAI (n = 6 rabbits per group), implants coated without antibiotics were associated with significantly increased knee width and in vivo BLI signals compared with implants coated with linezolid-rifampin (p < 0.001 and p < 0.05, respectively). On day 7, the implants without antibiotics were associated with significantly increased CFUs from tissue (mean [and standard error of the mean], 1.4 × 10 ± 2.1 × 10 CFUs; p < 0.001), bone (6.9 × 10 ± 3.1 × 10 CFUs; p < 0.05), and implant (5.1 × 10 ± 2.2 × 10 CFUs; p < 0.05) specimens compared with implants with linezolid-rifampin, which demonstrated no detectable CFUs from any source. CONCLUSIONS: By combining a bright bioluminescent MRSA strain with modified techniques, in vivo BLI in a rabbit model of OIAI demonstrated the efficacy of an antibiotic-releasing coating. CLINICAL RELEVANCE: The new capability of in vivo BLI for noninvasive monitoring of bacterial burden in larger-animal models of OIAI may have important preclinical relevance.
Authors: Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson Journal: Clin Infect Dis Date: 2012-12-06 Impact factor: 9.079
Authors: Nicholas M Bernthal; Jonathan R Pribaz; Alexandra I Stavrakis; Fabrizio Billi; John S Cho; Romela Irene Ramos; Kevin P Francis; Yoichiro Iwakura; Lloyd S Miller Journal: J Orthop Res Date: 2011-03-28 Impact factor: 3.494
Authors: Rabih O Darouiche; Mohammad D Mansouri; Devin Zakarevicz; Atef Alsharif; Glenn C Landon Journal: J Bone Joint Surg Am Date: 2007-04 Impact factor: 5.284
Authors: Jared A Niska; Jonathan H Shahbazian; Romela Irene Ramos; Kevin P Francis; Nicholas M Bernthal; Lloyd S Miller Journal: Antimicrob Agents Chemother Date: 2013-08-05 Impact factor: 5.191
Authors: V J Suhardi; D A Bichara; Sjj Kwok; A A Freiberg; H Rubash; H Malchau; S H Yun; O K Muratoglu; E Oral Journal: Nat Biomed Eng Date: 2017-06-13 Impact factor: 25.671
Authors: Joyce Craig; Thomas Fuchs; Michelle Jenks; Kelly Fleetwood; Dominik Franz; Joel Iff; Michael Raschke Journal: Int Orthop Date: 2014-02-15 Impact factor: 3.075
Authors: Nathan K Archer; Yu Wang; Roger V Ortines; Haiyun Liu; Sabrina J Nolan; Qi Liu; Martin P Alphonse; Dustin A Dikeman; Momina Mazhar; Robert J Miller; Leif S Anderson; Kevin P Francis; Scott I Simon; Lloyd S Miller Journal: Methods Mol Biol Date: 2020
Authors: Robert J Miller; Heidi A Crosby; Katrin Schilcher; Yu Wang; Roger V Ortines; Momina Mazhar; Dustin A Dikeman; Bret L Pinsker; Isabelle D Brown; Daniel P Joyce; Jeffrey Zhang; Nathan K Archer; Haiyun Liu; Martin P Alphonse; Julie Czupryna; William R Anderson; Nicholas M Bernthal; Lea Fortuno-Miranda; Jeff W M Bulte; Kevin P Francis; Alexander R Horswill; Lloyd S Miller Journal: Sci Rep Date: 2019-11-13 Impact factor: 4.379
Authors: Oren Gordon; Robert J Miller; John M Thompson; Alvaro A Ordonez; Mariah H Klunk; Dustin A Dikeman; Daniel P Joyce; Camilo A Ruiz-Bedoya; Lloyd S Miller; Sanjay K Jain Journal: Dis Model Mech Date: 2020-07-28 Impact factor: 5.758
Authors: Marjolein Heuker; Marina López-Álvarez; Jorrit W A Schoenmakers; Wouter B Nagengast; Gooitzen M van Dam; Jan Maarten van Dijl; Paul C Jutte; Marleen van Oosten Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 9.236
Authors: Alvaro A Ordonez; Matthew Fl Parker; Robert J Miller; Donika Plyku; Camilo A Ruiz-Bedoya; Elizabeth W Tucker; Justin M Luu; Dustin A Dikeman; Wojciech G Lesniak; Daniel P Holt; Robert F Dannals; Lloyd S Miller; Steven P Rowe; David M Wilson; Sanjay K Jain Journal: JCI Insight Date: 2022-01-11